Kisspeptin-54: Evidence-Based Review: Clinical Data and Practical Applications
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
An evidence-based review of Kisspeptin-54, a longer-acting form of kisspeptin, exploring its clinical data in fertility treatments, its practical applications, and a comparison with Kisspeptin-10.
Kisspeptin-54: A Sustained Approach to Reproductive Health
Kisspeptin-54 is the full-length, 54-amino-acid peptide hormone that, along with its shorter, more potent fragment Kisspeptin-10, governs the reproductive axis. While both peptides activate the same receptor (KISS1R), Kisspeptin-54 has a longer half-life, leading to a more sustained stimulation of the reproductive system. This property has made it a focus of research for applications requiring a more prolonged effect, such as in fertility treatments.
Clinical Data: A Boon for Assisted Reproduction
The most significant clinical application of Kisspeptin-54 to date is in the field of in vitro fertilization (IVF). A landmark study demonstrated that a single injection of Kisspeptin-54 can safely and effectively trigger oocyte (egg) maturation in women undergoing IVF, offering a new alternative to traditional methods that carry a risk of ovarian hyperstimulation syndrome (OHSS) [1]. Further research has confirmed the efficacy of Kisspeptin-54 for this purpose, even in women at high risk of OHSS [2].
Practical Applications: Beyond IVF
Beyond its use in IVF, Kisspeptin-54 is being explored for other practical applications in reproductive medicine:
Treatment of Hypothalamic Amenorrhea: The sustained action of Kisspeptin-54 makes it a potential treatment for women with hypothalamic amenorrhea, a condition where the hypothalamus fails to release GnRH, leading to a lack of menstrual periods.
Male Infertility: Kisspeptin-54 can stimulate testosterone production in men and is being investigated as a treatment for certain forms of male infertility.
Diagnostic Tool: The response to Kisspeptin-54 administration can be used as a diagnostic tool to assess the function of the hypothalamic-pituitary-gonadal axis.
Kisspeptin-54 vs. Kisspeptin-10: A Tale of Two Peptides
While both Kisspeptin-54 and Kisspeptin-10 activate the same receptor, their different pharmacokinetic profiles lead to distinct biological effects. A direct comparison in humans revealed that while Kisspeptin-10 is more potent on a molar basis, Kisspeptin-54 elicits a more sustained release of LH [3].
| Feature | Kisspeptin-54 | Kisspeptin-10 |
| :--- | :--- | :--- |
| Length | 54 amino acids | 10 amino acids |
| Half-life | Longer | Shorter |
| Effect | Sustained stimulation | Pulsatile stimulation |
| Primary Use | Oocyte maturation in IVF | Investigational for HSDD, pulsatile GnRH release |
Safety and Tolerability
Kisspeptin-54 has been shown to be safe and well-tolerated in clinical trials. The side effects are similar to those of Kisspeptin-10 and include mild and transient flushing, nausea, and headache. The ability of Kisspeptin-54 to trigger oocyte maturation without causing OHSS is a major safety advantage over traditional methods.
Key Takeaways
Kisspeptin-54 is a longer-acting form of kisspeptin that provides sustained stimulation of the reproductive axis.
It is a safe and effective method for triggering oocyte maturation in IVF, reducing the risk of OHSS.
It has potential applications in the treatment of hypothalamic amenorrhea and male infertility.
Compared to Kisspeptin-10, Kisspeptin-54 has a longer half-life and produces a more sustained effect.
> Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
References
[1] Jayasena, C. N., Abbara, A., Comninos, A. N., et al. (2014). Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. The Journal of clinical investigation, 124(8), 3667–3677. https://www.jci.org/articles/view/75730
[2] Abbara, A., Jayasena, C. N., Christopoulos, G., et al. (2015). Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. The Journal of clinical endocrinology and metabolism, 100(9), 3322–3331. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570165/
[3] Jayasena, C. N., Comninos, A. N., Narayanaswamy, S., et al. (2015). Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human reproduction*, 30(8), 1934–1941. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507333/
---